Literature DB >> 20223708

Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder.

Masaoki Iwanami1, Tomoyuki Miyamoto, Masayuki Miyamoto, Koichi Hirata, Etsuo Takada.   

Abstract

BACKGROUND: Substantia nigra (SN) hyperechogenicity determined by transcranial sonography (TCS) and olfactory dysfunction are common findings in Parkinson disease (PD), which may reveal a prodromal synucleinopathy in idiopathic REM sleep behavior disorder (iRBD).
METHODS: TCS and the Odor Stick Identification Test for Japanese (OSIT-J) were performed in 34 consecutive patients with iRBD (67.9+/-6.1years), 17 consecutive patients with PD (66.4+/-6.7years), and 21 control group subjects (64.4+/-5.8years).
RESULTS: There was a significantly increased area of echogenicity in the SN in the iRBD group (0.20+/-0.13cm2) and PD group (0.22+/-0.11cm2) compared with the control group (0.06+/-0.06cm(2)). We found pathological SN hyperechogenicity (0.20cm2) in 41.2% of the iRBD group, 52.6% of the PD group, and 9.5% of the control group. Further, there were abnormal findings of both pathological SN hyperechogenicity (0.20cm2) and functional anosmia or hyposmia in 4 (11.8%) or 9 (26.5%) of the iRBD group subjects, respectively, and 7 (57.9%) or 2 (11.8%) of the PD group subjects, respectively.
CONCLUSION: Pathological SN hyperechogenic abnormality and functional anosmia in iRBD may be a disease state in the transition to a neurodegenerative disease. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20223708     DOI: 10.1016/j.sleep.2009.12.006

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  15 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Advances in Biomarker Research in Parkinson's Disease.

Authors:  Shyamal H Mehta; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

Review 3.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

Review 4.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 5.  Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease.

Authors:  Bradley F Boeve
Journal:  Lancet Neurol       Date:  2013-04-09       Impact factor: 44.182

Review 6.  Idiopathic REM sleep behaviour disorder and neurodegeneration - an update.

Authors:  Birgit Högl; Ambra Stefani; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2017-11-24       Impact factor: 42.937

Review 7.  Parkinson's disease and sleep/wake disturbances.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Koichi Hirata
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 8.  Biomarkers in Parkinson's disease.

Authors:  John C Morgan; Shyamal H Mehta; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

Review 9.  REM sleep behaviour disorder in Parkinson's disease (Review).

Authors:  Ștefania Diaconu; Oana Falup-Pecurariu; Diana Țînț; Cristian Falup-Pecurariu
Journal:  Exp Ther Med       Date:  2021-05-28       Impact factor: 2.447

10.  Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease.

Authors:  Uwe Walter; Sabine Kleinschmidt; Florian Rimmele; Christian Wunderlich; Irene Gemende; Reiner Benecke; Knut Busse
Journal:  J Neurol       Date:  2013-10-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.